Spero Therapeutics' Robust Drug Pipeline and Positive Trial Advancements Prompt Buy RatingTipRanks Financial Blog • about 1 month ago
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Spero Therapeutics (SPRO Research Report), with a price...
Share to Feed
Related Stocks: NAS:SPRO...
On track for topline data from SPR720 Phase 2a proof-of-concept trial in treatment-naive and treatment-experienced non-refractory NTM-PD patients, expected in 2H 2024Initiated enrollment in PIVOT-PO...
Spero Therapeutics, Inc. ( NASDAQ:SPRO ) shares have continued their recent momentum with a 27% gain in the last month...
Spero Therapeutics Q4 2023 Earnings Preview...
Spero Therapeutics (NASDAQ:SPRO) publiera mercredi 13 mars son dernier rapport de r sultats. Le rapport suivant inclut l'opinion de Benzinga sur Spero Therapeutics.
D finition de b n fices, r sultat...
CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing...
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel...
CAMBRIDGE, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing...
Spero Therapeutics Inc (SPRO) has released an update to notify the public and investors about its officers. Tamara Joseph is resigning as Chief Leg...